Kaos Capital Calls on Capricor (NASDAQ: CAPR) Shareholders
Kaos Capital, a significant shareholder of Capricor Therapeutics, issued a letter demanding an immediate board meeting to address governance and strategy, including the nomination of two independent directors. The activist firm criticized the company's capital allocation, noting that cash decreased by $80.2 million to $237.9 million, while general and administrative expenses doubled to $23.5 million in the first half of the year.
Key figures
- G and a
- $23.5 million
- Cash balance
- $237.9 million
- Cash decrease
- $80.2 million
- Operating expense
- $79.7 million
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.